Advanced enteral therapy in acute pancreatitis: Is there a room for immunonutrition? A meta-analysis  by Petrov, Maxim S. et al.
i n t e rn a t i o n a l j o u rn a l o f s u r g e r y 6 ( 2 0 0 8 ) 1 1 9 – 1 2 4www. the i j s . comAdvanced enteral therapy in acute pancreatitis: Is there
a room for immunonutrition? A meta-analysisMaxim S. Petrov*, Vagif A. Atduev, Vladimir E. Zagainov
Department of Surgery, Nizhny Novgorod State Medical Academy, PO Box 568, Nizhny Novgorod 603000, Russiaa r t i c l e i n f o
Article history:
Received 8 January 2008
Accepted 15 January 2008
Published online 25 January 2008
Keywords:
Immunonutrition
Enteral nutrition
Acute pancreatitis
Complications
Mortality
Meta-analysis* Corresponding author. Tel.: þ7 910 383 396
E-mail address: max.petrov@gmail.com (
1743-9191/$ – see front matter ª 2008 Surgic
doi:10.1016/j.ijsu.2008.01.003a b s t r a c t
Background: It is believed that certain nutrients such as glutamine, arginine and omega-3
fatty acids may play a significant role in metabolic, inflammatory, and immune processes
in acute pancreatitis. The present systematic review aimed to define whether the addition
of these substances to enteral nutrition provides any clinical benefit over standard enteral
formulas in patients with acute pancreatitis.
Methods: A computerized search on electronic databases (Cochrane Central Register of Con-
trolled Trials, EMBASE and MEDLINE) and manual search of the abstracts of major gastro-
enterological meetings (UEGW, DDW) were undertaken. The studied outcomes were total
infectious complication, in-hospital mortality and length of hospital stay. The data were
meta-analyzed using a random-effects model.
Results: A total of three randomized controlled trials satisfied the inclusion criteria. When
compared with standard enteral nutrition, immunonutrition was not associated with the
significantly reduced risk of total infectious complications (risk ratio 0.82; 95% confidence
interval 0.44–1.53; P¼ 0.53) and death (risk ratio 0.64; 95% confidence interval 0.20–2.07;
P¼ 0.46). Mean difference in length of hospital stay between two groups was not significant
(P¼ 0.80).
Conclusions: There is no evidence that enteral nutrition supplemented with glutamine,
arginine and/or omega-3 fatty acids, in comparison with standard enteral nutrition, has
any beneficial effect on infectious complications, mortality or length of hospital stay in
acute pancreatitis. The pursuit of new compositions of enteral formulations in this cate-
gory of patients may be advocated.
ª 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction have immune-enhancing properties, glutamine, arginine,During the last decade, advancements in the nutritional man-
agement of patients with acute pancreatitis have established
enteral feeding as an essential element of the treatment.1–3
Because the gastrointestinal tract is the largest immune organ
in the body, containing around 65% of immune tissue overall,
the use of immune-enhanced enteral formulations may fur-
ther amplify the beneficial effect of intra-luminal therapy in
acute pancreatitis.4,5 Of the various nutrients that thought to3; fax: þ1 801 788 7383.
M.S. Petrov).
al Associates Ltd. Publishomega-3 fatty acids and nucleotides have been advocated
for use both separately and in combined preparations.6,7 The
feeding formulas on the basis of these substances had positive
effects on the rate of infectious complications in different
experimental settings, including acute pancreatitis.8,9
There was also a number of clinical studies, which sug-
gested that immunonutrition may have a potential to modify
the inflammatory response. The results of randomized controlled
trials (RCTs) that compared the use of immune-enhanceded by Elsevier Ltd. All rights reserved.
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threemeta-analyses.10–12 Themost recent and comprehensive
systematic review of 2419 patients from22 RCTs found that the
effect of immune-enhancing enteral nutrition may depend on
the subset of the analyzed patients.12 In particular, there was
no effect of immunonutrition on the risk of infectious compli-
cations or death within the subgroup of critically ill patients
only. At the same time, administration of high-arginine-con-
tent formulas (12–15 g/L) in a combined group of critically ill
and elective surgery patients were associated with a statisti-
cally significant reduction in infectious complications and
a trend to a lower mortality in comparison with other im-
mune-enhancing diets. In its turn, the use of high- and low-
arginine-content formulas was associated with a significantly
lower risk of infectious complications in elective surgery
patients when compared with critically ill patients.
However, due to the fact that patients with acute pancrea-
titis may be referred to both the critically ill group and the
elective surgery group, the real clinical applicability of
‘‘immunoactive’’ enteral formulations in patients with acute
pancreatitis is still unknown. Thereby, our aim is to define
a clinical effect of immunonutrition in the setting of acute
pancreatitis on the basis of reviewing of all RCTs on im-
mune-enhanced versus standard enteral nutrition.Not RCTs
comparing immunonutrition
and standard enteral nutrition
(n=24)
Not RCTs
on enteral nutrition
(n=181)
RCTs on enteral nutrition
(n=27)
Potentially relevant
publications identified
(n=208)
RCTs included in meta-analysis
(n=3)
Fig. 1 – Identification of eligible randomized controlled
trials.2. Methods
2.1. Study identification
A computerized literature search on three databases (MED-
LINE, EMBASEandCochraneCentral Register of Controlled Tri-
als) from January 1, 1990 to December 1, 2007 was performed.
The search strategy for MEDLINE was ‘‘acute pancreatitis’’
[Title/Abstract] AND (‘‘enteral nutrition’’ [Title/Abstract] OR
‘‘enteral feeding’’ [Title/Abstract]) OR (‘‘glutamine’’ [Title/
Abstract] OR ‘‘arginine’’ [Title/Abstract] OR ‘‘omega-3 fatty
acids’’ [Title/Abstract]) OR (‘‘nucleotides’’ [Title/Abstract]) OR
(‘‘immunonutrition’’ [Title/Abstract]). The search strategy for
EMBASE was ‘‘acute pancreatitis’’ AND (‘‘immunonutrition’’
OR ‘‘immune-enhanced formulas’’) AND [humans]/lim. The
search strategy in Cochrane library was ‘‘acute pancreatitis’’
AND (‘‘enteral nutrition’’ OR ‘‘enteral feeding’’) AND (‘‘immu-
nonutrition’’ OR ‘‘immune-enhanced formulas’’).
An additional search was done using the references of the
original articles and abstracts of major gastroenterological
meetings (DDW, UEGW) from 2001 to 2007. No language re-
strictions were applied.
2.2. Study selection criteria
The criteria for trial inclusion were as follows:
(1) The target population consisted of patients with acute
pancreatitis.
(2) RCT was included if the intervention arm received enter-
ally a feed supplemented with glutamine and/or arginine
and/or omega-3 fatty acids and/or nucleotides (immuno-
nutrition); the control arm had to receive an enteralfeeding without above-mentioned supplements (standard
enteral nutrition).
(3) Clinical outcomemeasureswere total infectious complica-
tion, in-hospital mortality and/or length of hospital stay.2.3. Data acquisition and quality assessment
Two authors independently applied the inclusion criteria to
the relevant publications and abstracted the data from the
articles. Methodological quality of included studies was
assessed using a previously published quality score.12 It con-
sists of nine parameters (randomization, analysis, blinding,
patient selection, comparability of groups at baseline, extent
of follow-up, treatment protocol, cointerventions and out-
comes) with quality score range from 0 to 14 points.
2.4. Statistical analysis
The data analysis was performed using the meta-analysis
software (Bax L., Yu L.M., Ikeda N., Tsuruta N., Moons K.G.M.
MIX: Comprehensive Free Software for Meta-analysis of
Causal Research Data – Version 1.51. 2006). Data on infectious
complication and mortality were combined to determine risk
ratio (RR), with its 95% confidence interval (CI). The continu-
ous outcomes of hospital stay were combined using the
mean difference method. The presence of heterogeneity was
assessed using I2 measure, with I2> 0.2 indicating significant
heterogeneity. Irrespective of the degree of heterogeneity of
effect among the included trials, a random-effects model
was used. Possible biases were explored by funnel plots.3. Results
A total of 208 publications were initially retrieved, fromwhich
27 RCTs concerning enteral nutrition in acute pancreatitis
were identified Fig. 1. Twenty-four trials were excluded for
the following reasons:
Table 1 – Summary of study characteristics for the included trials
Study Methodological
quality of studiesa
Severity
(score)b
Mild:severe acute
pancreatitis, patientsb
Supplemented
nutrients
Sitting of
tube
Feeding
start
Duration
of nutrition,
days
Hallay et al.37 6 3.6 (3–5)/3.9 (3–6)
(Ranson)
0:11/0:8 Glutamine,
arginine
Endoscopic <24 h of
admission
5
Lasztity et al.38 8 8 (5–12)/7.6 (5–13)
(APACHE II)
11:3/11:3 Omega-3
fatty acids
Endoscopic <24 h of
admission
10.6 6.7/
17.6 10.5b
Pearce et al.39 11 9 (8–19)/9.5 (8–16)
(APACHE II)
0:15/0:16 Glutamine,
arginine,
omega-3
fatty acids
Blind
(Bengmark’s
tube)c
<72 h after
onset
3–15
a The range of the quality score is 0–14.
b Immunonutrition/standard enteral nutrition.
c Three patients had endoscopic placement of a nasojejunal tube and one had a needle jejunostomy at laparotomy.
Table 2 – Summary of clinical outcomes for the included trials
Study Number of patientsa Mortalitya Total infectious
complicationsa
Length of stay, daysa
Hallay et al.37 11/8 3/2 2/3 Not stated
Lasztity et al.38 14/14 1/2 5/7 13.0 7.7/19.3 7.2
Pearce et al.39 15/16 0/3 5/4 19.1 14.4/13.4 11.1
a Immunonutrition/standard enteral nutrition.
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(2) oral feeding was compared with nasojejunal15;
(3) polymeric and semi-elemental enteral formulas were
compared16;
(4) effect of prebiotics and probiotics was evaluated17–19;
(5) enteral nutrition was compared with parenteral nutri-
tion20–33 and nil-per-os regimen34;
(6) combination of enteral and parenteral nutrition was com-
pared with parenteral nutrition.35,36
Eventually, three RCTs met all the inclusion criteria.37–39
Overall, 78 patients were enrolled in the studies, of which 40
were allocated to the immunonutrition group, whereas 38
were randomized to standard enteral nutrition. Table 1 pres-
ents the study characteristics for the included trials. Formal
assessment of the funnel plot did not yield any evidence of
a publication bias.Study IN EN
Hallay et al. 2/11 3/8
Lasztity et al. 5/14 7/14
Pearce et al. 5/15 4/16
META-ANALYSIS: 12/40 14/38
0,1
Fores
R
Fig. 2 – Random-effects model of relative risk of infectious comp
with standard enteral nutrition.All RCTs reported the number of total infectious complica-
tions (Table 2). A total of 26 patients suffered any infectious
complication, 12 of 40 (30%) in the immunonutrition group
and 14 of 38 (37%) in the standard enteral nutrition group.
As it is depicted on Fig. 2, the use of immuno-enriched nutri-
tional formula was not associated with a significant reduction
in the risk of infectious complications (RR 0.82; 95% CI 0.44 to
1.53; P¼ 0.53). The I2 measure for heterogeneity was 0.
Eleven of 78 (14%) patients died, four in the immunonutri-
tion group and seven in the standard enteral nutrition group
(Table 2). When the three included trials presenting data on
mortality were aggregated, no statistically significant mortal-
ity benefit was evident for the use of immunonutrition (RR
0.64; 95% CI 0.20–2.07; P¼ 0.46; Fig. 3). There was no significant
heterogeneity between trials (I2¼ 0).
Two studies reported on length of hospital stay (Table 2).
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with 95% CI
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Fig. 3 – Random-effects model of relative risk of death associated with immunonutrition in comparison with standard
enteral nutrition.
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ence0.87; 95%CI12.57 to 10.84; P¼ 0.80). Therewas a signif-
icant heterogeneity between studies (I2¼ 57.2).4. Discussion
This systematic review failed to show any clinical beneficial
effect of enteral nutrition supplemented with glutamine, argi-
nine and/or omega-3 fatty acids, when compared with stan-
dard enteral nutrition, in patients with acute pancreatitis.
On the surface, as the sample size of the present meta-
analysis is fairly small, it seems that no definitive conclusions
can be drawn from it. Nevertheless, a conducted meta-analy-
sis of critically ill and elective surgery patients,12 which was
greater in terms of study population, found a statistically sig-
nificant benefit of immunonutrition (reduced risk of infec-
tious complications) only in the subgroup of patients who
received high-arginine-content formulas. However, excessive
supplementing of arginine could potentially lead to a pancreas
damaging effect,38,40 probably due to the excessive produc-
tion of nitric oxide.41,42 It is also known that administration
of omega-3 fatty acids decreases antioxidant capacity.43 Nev-
ertheless, the relevance of these experimental observations is
difficult to evaluate in clinical setting because immunonutri-
tion is usually administered in a compound and it is hard to
ascribe a beneficial or harmful effect of immunonutritional
formulation to any single immune-enhancing agent. More-
over, it was shown that a single ‘‘immunoactive’’ substance
(such as arginine or omega-3 fatty acids) can be associated
with opposite effects on systemic inflammation.44
Influence of nutrition on markers of systemic inflamma-
tory response syndrome (SIRS) in acute pancreatitis was
investigated in a number of RCTs. By demonstrating a signifi-
cant reduction in serum C-reactive protein (CRP) concentra-
tion and number of patients with SIRS before and after
nutrition in the enterally fed over parenterally fed patients
with severe acute pancreatitis, the early RCT from the UK23
raised an optimism regarding the expeditious influence of
enteral nutrients on the inflammatory cascade and immune
defense mechanisms in acute pancreatitis. However, the
subsequent RCTs showed that enteral nutrition did not signif-
icantly change CRP level in comparison both with parenteral
nutrition29,30,32,33 and with nil-per-os regimen.34 Moreover,CRP concentration was significantly lower by day 3 of feeding
in the standard enteral nutrition group when compared to the
immunonutrition group.39 Similarly, enteral over parenteral
nutrition,33 enteral feeding over fasting,34 immunonutrition
over standard enteral feeding39 did not affect the level of cyto-
kines. In part, it might be due to the fact that enteral nutrition
increases mesenteric lymph flow, permitting toxic factors in
mesenteric lymph to maintain an inflammatory response
while bypassing the portal circulation and liver.45
It should be also realized that immunonutrition has an in-
trinsic limitation in the clinical setting because enteral feeding
usually requires a progressive increase of the infusion rate
during the first 2–3 days to be tolerated while reaching the tar-
get rate. Thereby, the amount of immune-enhancing sub-
strates given in the first days might be insufficient to produce
a prompt modulation of the host response. At the same time,
it is known that the first 48–72 h period after the onset of acute
pancreatitis (so-called ‘‘therapeutic window’’) is the best pe-
riod for prevention/attenuation of the inflammatory response
and applying treatment modalities.46 Another marked draw-
back is the cost-effectiveness of ‘‘immunoactive’’ formulas,
which is substantially higher than that of a standard enteral
diet.47 All things considered, even though a formal interpreta-
tion of the results of our systematic reviewmay require a new
large-scale RCT on immunonutrition, a prudent insight would
recommend to investigate another substances which may
modify a standard enteral feed and potentially have a benefi-
cial clinical implication in acute pancreatitis.
In conclusion, it seems that the addition of glutamine, argi-
nine and/or omega-3 fatty acids to the enteral feed has no
beneficial impact on the course of acute pancreatitis. At the
same time, the continued refinement of intra-luminal therapy
may potentially have an exciting clinical implication in acute
pancreatitis through preserving the innate gut barrier func-
tion and boosting the immune system.
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